Should I buy or sell Anika Therapeutics stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Anika Therapeutics in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ANIK shares. View ANIK analyst ratings or view top-rated stocks .

What is Anika Therapeutics' stock price target for 2024?

2 Wall Street research analysts have issued 1-year price objectives for Anika Therapeutics' shares. Their ANIK share price targets range from $22.00 to $37.00. On average, they expect the company's stock price to reach $29.50 in the next year. This suggests a possible upside of 16.0% from the stock's current price. View analysts price targets for ANIK or view top-rated stocks among Wall Street analysts .

How have ANIK shares performed in 2024?

Anika Therapeutics' stock was trading at $22.66 at the start of the year. Since then, ANIK stock has increased by 12.2% and is now trading at $25.43. View the best growth stocks for 2024 here .

When is Anika Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our ANIK earnings forecast .

How were Anika Therapeutics' earnings last quarter?

Anika Therapeutics, Inc. (NASDAQ:ANIK) issued its quarterly earnings results on Wednesday, March, 13th. The biotechnology company reported $0.05 earnings per share for the quarter, topping analysts' consensus estimates of ($0.15) by $0.20. The biotechnology company had revenue of $42.97 million for the quarter, compared to analyst estimates of $41.51 million. Anika Therapeutics had a negative trailing twelve-month return on equity of 2.10% and a negative net margin of 49.60%.

What ETF holds Anika Therapeutics' stock?

Invesco Nasdaq Future Gen 200 ETF holds 1,676 shares of ANIK stock, representing 0.54% of its portfolio.

What guidance has Anika Therapeutics issued on next quarter's earnings?

Anika Therapeutics issued an update on its FY 2024 earnings guidance on Wednesday, March, 13th. The company provided EPS guidance of for the period. The company issued revenue guidance of $168.0 million-$173.0 million, compared to the consensus revenue estimate of $179.4 million.

What other stocks do shareholders of Anika Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Anika Therapeutics investors own include Alibaba Group (BABA) , Broadcom (AVGO) , Gilead Sciences (GILD) , Micron Technology (MU) , Skyworks Solutions (SWKS) , Tesla (TSLA) , Advanced Micro Devices (AMD) , CVS Health (CVS) , Enterprise Products Partners (EPD) and Ligand Pharmaceuticals (LGND) .

Who are Anika Therapeutics' major shareholders?

Anika Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Allspring Global Investments Holdings LLC (0.44%). Insiders that own company stock include Cheryl R Blanchard, David Colleran, Jeffery S Thompson, John B Henneman III , Michael L Levitz and Raymond J Land . View institutional ownership trends .

How do I buy shares of Anika Therapeutics?

Shares of ANIK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:ANIK

Anika Therapeutics (ANIK) Stock Price, News & Analysis

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)

Free ANIK Stock Alerts

$25.43

-0.26 (-1.01%)

(As of 04/18/2024 ET)

Compare

Today's Range: $25.37
▼
$25.81
50-Day Range: $23.31
▼
$26.42
52-Week Range: $16.54
▼
$28.58

Volume: 83,322 shs
Average Volume: 82,151 shs
Market Capitalization: $377.64 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $29.50

Get Anika Therapeutics alerts:

Anika Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 16.0% Upside
$29.50 Price Target
Short Interest: Bearish
5.44% of Float Sold Short
Dividend Strength: N/A
Sustainability: -2.12
Upright™ Environmental Score
News Sentiment: 0.00
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: 20.54%
From $1.12 to $1.35 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.73 out of 5 stars

Medical Sector

409th out of 918 stocks

Surgical & Medical Instruments Industry

41st out of 91 stocks

2.3

Analyst's Opinion

Consensus Rating
Anika Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
Anika Therapeutics has only been the subject of 2 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
5.44% of the float of Anika Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Anika Therapeutics has a short interest ratio ("days to cover") of 9.
Change versus previous month
Short interest in Anika Therapeutics has recently increased by 0.56%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Anika Therapeutics does not currently pay a dividend.
Dividend Growth
Anika Therapeutics does not have a long track record of dividend growth.

3.6

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Anika Therapeutics has received a 44.00% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Synthetic bone grafts", "Medical splints", and "Medical screws" products. See details.
Environmental Sustainability
The Environmental Impact score for Anika Therapeutics is -2.12.

0.6

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 2 news articles for Anika Therapeutics this week, compared to 1 article on an average week.
MarketBeat Follows
3 people have added Anika Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Anika Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 5.85% of the stock of Anika Therapeutics is held by insiders.
Percentage Held by Institutions
91.53% of the stock of Anika Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.9

Earnings and Valuation

Earnings Growth
Earnings for Anika Therapeutics are expected to grow by 20.54% in the coming year, from $1.12 to $1.35 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Anika Therapeutics is -4.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Anika Therapeutics is -4.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Growth Ratio
Anika Therapeutics has a PEG Ratio of 2.28. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Anika Therapeutics has a P/B Ratio of 1.75. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Crypto 101 Media

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

About Anika Therapeutics Stock (NASDAQ:ANIK)

Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide both short- and long-term pain relief. The company's joint preservation and restoration product family comprises and orthopedic regenerative solutions, including Hyalofast and Tactoset; sports medicine solutions used to repair and reconstruct damaged ligaments and tendons; and preserving joint solutions, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants, which are designed to treat upper and lower extremity orthopedic conditions. In addition, it offers non-orthopedic products comprising HA-based products for non-orthopedic applications including Hyvisc, a molecular weight injectable HA veterinary product; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and Hyalomatrix used for the treatment of burns and ulcers, as well as products used for the treatment of ears, nose and throat disorders, and ophthalmic products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.

ANIK Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ANIK Stock News Headlines

April 18, 2024 | finance.yahoo.com

Anika to Issue First Quarter 2024 Financial Results on Wednesday, May 8, 2024

April 18, 2024 | globenewswire.com

Anika to Issue First Quarter 2024 Financial Results on Wednesday, May 8, 2024

April 18, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

April 9, 2024 | americanbankingnews.com

Anika Therapeutics (NASDAQ:ANIK) Stock Price Passes Above 200-Day Moving Average of $22.38

April 2, 2024 | globenewswire.com

Anika to Participate in the 23rd Annual Needham Virtual Healthcare Conference

March 28, 2024 | msn.com

Viking Therapeutics stock jumps more than 15% on promising weight loss pill data

March 16, 2024 | finance.yahoo.com

Anika Therapeutics, Inc. (NASDAQ:ANIK) Q4 2023 Earnings Call Transcript

March 15, 2024 | markets.businessinsider.com

Anika Therapeutics: Strong Q4 Performance and Upbeat FY2024 Outlook Justify Buy Rating and Raised Price Target

April 18, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

March 14, 2024 | finanznachrichten.de

Anika Therapeutics Inc.: Anika Reports Fourth Quarter and Year-End 2023 Financial Results

March 14, 2024 | marketwatch.com

Anika Therapeutics to Cut Workforce by 9% in Push for Profitability

March 13, 2024 | globenewswire.com

Anika Reports Fourth Quarter and Year-End 2023 Financial Results

March 12, 2024 | msn.com

Anika Therapeutics Q4 2023 Earnings Preview

March 12, 2024 | seekingalpha.com

ADC Therapeutics Q4 Earnings Preview

March 12, 2024 | benzinga.com

Earnings Outlook For Anika Therapeutics

March 8, 2024 | globenewswire.com

Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 8, 2024 | reuters.com

Europe waits on ECB as BOJ lights up the yen

March 7, 2024 | finance.yahoo.com

Fifth Annual MedExecWomen Conference in April to Discuss This Year’s Top Opportunities in Medtech

March 7, 2024 | msn.com

Activist investor Caligan discloses 9.7% stake in Anika, nominates two director candidates

March 1, 2024 | finance.yahoo.com

Viscosupplementation Market to Reach US$ 7.81 Billion by 2030: A Comprehensive Analysis of Industry Trends, Growth Drivers, and Market Share

February 27, 2024 | globenewswire.com

Anika to Issue Fourth Quarter and Year-End 2023 Financial Results on Wednesday, March 13, 2024

February 21, 2024 | finance.yahoo.com

Anika Therapeutics Inc (AKP.BE)

February 15, 2024 | finance.yahoo.com

Stoke Therapeutics, Inc. (STOK) Stock Jumps 25.5%: Will It Continue to Soar?

February 6, 2024 | finance.yahoo.com

Pixelgen Technologies and Australian Biosearch Announce Distribution Agreement

February 6, 2024 | ca.finance.yahoo.com

Anika Therapeutics, Inc. (ANIK)

January 22, 2024 | finance.yahoo.com

Viscosupplementation Market Size Worth USD 10.51 Billion in 2032 | Emergen Research

January 18, 2024 | finance.yahoo.com

Is There An Opportunity With Anika Therapeutics, Inc.'s (NASDAQ:ANIK) 50% Undervaluation?

See More Headlines

Receive ANIK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Anika Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/13/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/14/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Surgical & medical instruments
Sub-Industry: Health Care Supplies
Current Symbol: NASDAQ:ANIK
CUSIP: 03525510
CIK: 898437
Web: www.anikatherapeutics.com
Phone: (781) 457-9000
Fax: 781-305-9720
Employees: 357
Year Founded: 1992

Price Target and Rating

Average Stock Price Target: $29.50
High Stock Price Target: $37.00
Low Stock Price Target: $22.00
Potential Upside/Downside: +16.0%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($5.65)
Trailing P/E Ratio: N/A
Forward P/E Ratio: 22.71
P/E Growth: 2.28
Net Income: $-82,670,000.00
Net Margins: -49.60%
Pretax Margin: -51.20%
Return on Equity: -2.10%
Return on Assets: -1.71%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 5.26
Quick Ratio: 3.76

Sales & Book Value

Annual Sales: $166.66 million
Price / Sales: 2.27
Cash Flow: $4.91 per share
Price / Cash Flow: 5.18
Book Value: $14.50 per share
Price / Book: 1.75

Miscellaneous

Outstanding Shares: 14,850,000
Free Float: 13,981,000
Market Cap: $377.64 million
Optionable: Optionable
Beta: 0.76

Social Links

The 10 Best AI Stocks to Own in 2024

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

Dr. Cheryl Renee Blanchard Ph.D. (Age 60)
President, CEO & Director
Comp: $1.31M
Mr. Michael L. Levitz (Age 50)
Executive VP, CFO & Treasurer
Comp: $710.6k
Mr. David Colleran J.D. (Age 52)
Executive VP, General Counsel & Corporate Secretary
Comp: $664.54k
Ms. Anne Nunes (Age 55)
Senior VP & COO
Mr. Ian W. McLeod
VP & Chief Accounting Officer
Mr. Mark Namaroff (Age 61)
Executive Director of Investor Relations & Corporate Communications
Mr. James Chase
Senior Vice President of International Sales & Marketing
Mr. Ben Joseph
Vice President of Commercial & Corporate Development
Ms. Lisa Funiciello
Vice President of Human Resources

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

ANIK Stock Analysis - Frequently Asked Questions

Should I buy or sell Anika Therapeutics stock right now?: 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Anika Therapeutics in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ANIK shares.
View ANIK analyst ratings or view top-rated stocks.
What is Anika Therapeutics' stock price target for 2024?: 2 Wall Street research analysts have issued 1-year price objectives for Anika Therapeutics' shares. Their ANIK share price targets range from $22.00 to $37.00. On average, they expect the company's stock price to reach $29.50 in the next year. This suggests a possible upside of 16.0% from the stock's current price.
View analysts price targets for ANIK or view top-rated stocks among Wall Street analysts.
How have ANIK shares performed in 2024?: Anika Therapeutics' stock was trading at $22.66 at the start of the year. Since then, ANIK stock has increased by 12.2% and is now trading at $25.43.
View the best growth stocks for 2024 here.
When is Anika Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our ANIK earnings forecast.
How were Anika Therapeutics' earnings last quarter?: Anika Therapeutics, Inc. (NASDAQ:ANIK) issued its quarterly earnings results on Wednesday, March, 13th. The biotechnology company reported $0.05 earnings per share for the quarter, topping analysts' consensus estimates of ($0.15) by $0.20. The biotechnology company had revenue of $42.97 million for the quarter, compared to analyst estimates of $41.51 million. Anika Therapeutics had a negative trailing twelve-month return on equity of 2.10% and a negative net margin of 49.60%.
What ETF holds Anika Therapeutics' stock?: Invesco Nasdaq Future Gen 200 ETF holds 1,676 shares of ANIK stock, representing 0.54% of its portfolio.

What guidance has Anika Therapeutics issued on next quarter's earnings?: Anika Therapeutics issued an update on its FY 2024 earnings guidance on Wednesday, March, 13th. The company provided EPS guidance of for the period. The company issued revenue guidance of $168.0 million-$173.0 million, compared to the consensus revenue estimate of $179.4 million.
What other stocks do shareholders of Anika Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Anika Therapeutics investors own include Alibaba Group (BABA), Broadcom (AVGO), Gilead Sciences (GILD), Micron Technology (MU), Skyworks Solutions (SWKS), Tesla (TSLA), Advanced Micro Devices (AMD), CVS Health (CVS), Enterprise Products Partners (EPD) and Ligand Pharmaceuticals (LGND).
Who are Anika Therapeutics' major shareholders?: Anika Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Allspring Global Investments Holdings LLC (0.44%). Insiders that own company stock include Cheryl R Blanchard, David Colleran, Jeffery S Thompson, John B Henneman III, Michael L Levitz and Raymond J Land.
View institutional ownership trends.
How do I buy shares of Anika Therapeutics?: Shares of ANIK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ANIK) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Anika Therapeutics (ANIK) Stock Price, News & Analysis

Anika Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Coverage This Week

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Anika Therapeutics Stock (NASDAQ:ANIK)

ANIK Stock Price History

ANIK Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Institutional Ownership

ANIK Stock Analysis - Frequently Asked Questions

Overall MarketRank^™